218 related articles for article (PubMed ID: 10764362)
21. Adverse Drug Reactions in Hospitalized Pediatric Patients: A Prospective Observational Study.
Kurian J; Mathew J; Sowjanya K; Chaitanya KR; Ramesh M; Sebastian J; Narayanappa D
Indian J Pediatr; 2016 May; 83(5):414-9. PubMed ID: 26916890
[TBL] [Abstract][Full Text] [Related]
22. Drug-induced tics: An observational postmarketing study.
Touafchia D; Montastruc F; Lapeyre-Mestre M; Rousseau V; Chebane L; Revet A
Hum Psychopharmacol; 2020 Jul; 35(4):e2734. PubMed ID: 32352603
[TBL] [Abstract][Full Text] [Related]
23. [Adverse drug reactions in children: 10 years of pharmacovigilance].
Damien S; Patural H; Trombert-Paviot B; Beyens MN
Arch Pediatr; 2016 May; 23(5):468-76. PubMed ID: 27062190
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database.
Taugourdeau-Raymond S; Rouby F; Default A; Jean-Pastor MJ;
Eur J Clin Pharmacol; 2012 Jul; 68(7):1103-7. PubMed ID: 22349162
[TBL] [Abstract][Full Text] [Related]
25. Drug-related admissions and hospital-acquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data.
Stausberg J; Hasford J
BMC Health Serv Res; 2011 May; 11():134. PubMed ID: 21619706
[TBL] [Abstract][Full Text] [Related]
26. Drug-induced hypersensitivity: A 5-year retrospective study in a hospital electronic health records database.
Mendes D; Alves C; Loureiro M; Fonte A; Batel-Marques F
J Clin Pharm Ther; 2019 Feb; 44(1):54-61. PubMed ID: 30069891
[TBL] [Abstract][Full Text] [Related]
27. [Adverse drug reactions reported to the Brazilian pharmacovigilance system from 2008 to 2013: descriptive study].
Mota DM; Vigo Á; Kuchenbecker RS
Cad Saude Publica; 2019 Aug; 35(8):e00148818. PubMed ID: 31460613
[TBL] [Abstract][Full Text] [Related]
28. Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System.
Sun J; Deng X; Chen X; Huang J; Huang S; Li Y; Feng J; Liu J; He G
Clin Pharmacol Ther; 2020 Oct; 108(4):791-797. PubMed ID: 32324898
[TBL] [Abstract][Full Text] [Related]
29. Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire.
Assi SB; Aba YT; Yavo JC; Nguessan AF; Tchiekoi NB; San KM; Bissagnéné E; Duparc S; Lameyre V; Tanoh MA
Malar J; 2017 Jan; 16(1):8. PubMed ID: 28049523
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous Adverse Drug Reaction Monitoring in a Tertiary Care Centre.
Kaur K; Kanwal P; Goyal P; Singh P; Yakhmi S; Jain S; Kaushal S
Curr Drug Saf; 2020; 15(3):215-221. PubMed ID: 32735525
[TBL] [Abstract][Full Text] [Related]
31. Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database.
Quillet A; Colin O; Bourgeois N; Favrelière S; Ferru A; Boinot L; Lafay-Chebassier C; Perault-Pochat MC
Fundam Clin Pharmacol; 2018 Apr; 32(2):227-233. PubMed ID: 29143369
[TBL] [Abstract][Full Text] [Related]
32. Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November, 2014.
Awodele O; Ibrahim A; Orhii P
Int J Risk Saf Med; 2016 Mar; 28(1):13-23. PubMed ID: 27176753
[TBL] [Abstract][Full Text] [Related]
33. Drugs and Sleep Apneas? A review of the French Pharmacovigilance database.
Linselle M; Montastruc F; Jantzen H; Valnet-Rabier MB; Haramburu F; Coquerel A; Gouraud A; Perault-Pochat MC; Bagheri H; Montastruc JL
Therapie; 2015; 70(4):347-50. PubMed ID: 25679185
[TBL] [Abstract][Full Text] [Related]
34. Incidence and cost estimate of treating pediatric adverse drug reactions in Lagos, Nigeria.
Oshikoya KA; Chukwura H; Njokanma OF; Senbanjo IO; Ojo I
Sao Paulo Med J; 2011 May; 129(3):153-64. PubMed ID: 21755250
[TBL] [Abstract][Full Text] [Related]
35. Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database.
Kaguelidou F; Beau-Salinas F; Jonville-Bera AP; Jacqz-Aigrain E
Br J Clin Pharmacol; 2016 Oct; 82(4):1058-68. PubMed ID: 27276109
[TBL] [Abstract][Full Text] [Related]
36. Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China.
Qing-ping S; Xiao-dong J; Feng D; Yan L; Mei-ling Y; Jin-xiu Z; Shu-qiang Z
BMC Health Serv Res; 2014 Feb; 14():73. PubMed ID: 24533894
[TBL] [Abstract][Full Text] [Related]
37. Trends of adverse drug reactions related-hospitalizations in Spain (2001-2006).
Carrasco-Garrido P; de Andrés LA; Barrera VH; de Miguel GA; Jiménez-García R
BMC Health Serv Res; 2010 Oct; 10():287. PubMed ID: 20942906
[TBL] [Abstract][Full Text] [Related]
38. [Importance of pharmacovigilance in current medical practice].
Ponte ML; Ragusa M; Armenteros C; Wachs A
Medicina (B Aires); 2013; 73(1):35-8. PubMed ID: 23335704
[TBL] [Abstract][Full Text] [Related]
39. Hospitalization trends, costs, and risk factors in HIV-infected children on antiretroviral therapy.
Collins IJ; Cairns J; Jourdain G; Fregonese F; Nantarukchaikul M; Lertpienthum N; Wannarit P; Attavinijtrakarn P; Layangool P; Le Coeur S; Lallemant M;
AIDS; 2012 Sep; 26(15):1943-52. PubMed ID: 22824633
[TBL] [Abstract][Full Text] [Related]
40. Measurement of the incidence of care-associated adverse events at the Department of Pediatrics of a teaching hospital.
Fajreldines A; Schnitzler E; Torres S; Panattieri N; Pellizzari M
Arch Argent Pediatr; 2019 Apr; 117(2):e106-e109. PubMed ID: 30869486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
